The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients

Matteo Lambertini, Massimo Di Maio, Olivia Pagani, Giuseppe Curigliano, Francesca Poggio, Lucia Del Mastro, Shani Paluch-Shimon, Sibylle Loibl, Ann H Partridge, Isabelle Demeestere, Hatem A Azim, Fedro A Peccatori

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Fertility and pregnancy-related issues are major concerns for young breast cancer patients. Limited data are available on physicians' knowledge, attitudes and practice in these fields.

METHODS: A 26-item questionnaire exploring 3 different topics (fertility preservation, pregnancy after breast cancer and breast cancer during pregnancy) was sent by email to physicians attending the 2016 3rd European School of Oncology (ESO) - European Society for Medical Oncology (ESMO) Breast Cancer in Young Women Conference (BCY3) and the 15th St. Gallen International Breast Cancer Conference 2017 (BCC 2017). Given the selected sample, survey respondents were expected to have a higher than average interest in the management of breast cancer patients. Descriptive analyses were performed.

RESULTS: A total of 273 physicians (105 at BCY3 and 168 at BCC 2017) completed the survey; 37.0%, 46.9% and 34.8% reported never having consulted the available international guidelines on fertility preservation, pregnancy after breast cancer and management of breast cancer during pregnancy, respectively. Up to 18.3% of respondents did not know if the different fertility preservation options were available in their country; 22.3% suggested that controlled ovarian stimulation should not be considered safe in patients with hormone receptor-positive disease. A total of 30.4% of respondents agreed or were neutral on the statement that pregnancy in breast cancer survivors may increase the risk of recurrence. Regarding breast cancer during pregnancy, 23.8% and 38.1% disagreed or were neutral on the statements that endocrine therapy and anti-HER2 agents should be avoided during pregnancy, respectively.

CONCLUSIONS: Further educational initiatives are needed to improve physicians' knowledge and adherence to available guidelines when addressing fertility and pregnancy-related issues in young breast cancer patients.

Original languageEnglish
Pages (from-to)41-49
Number of pages9
JournalBreast
Volume42
DOIs
Publication statusE-pub ahead of print - Aug 22 2018

Fingerprint

Health Knowledge, Attitudes, Practice
Fertility
Breast Neoplasms
Physicians
Pregnancy
Fertility Preservation
Surveys and Questionnaires
Guidelines
faropenem medoxomil
Ovulation Induction

Cite this

The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. / Lambertini, Matteo; Di Maio, Massimo; Pagani, Olivia; Curigliano, Giuseppe; Poggio, Francesca; Del Mastro, Lucia; Paluch-Shimon, Shani; Loibl, Sibylle; Partridge, Ann H; Demeestere, Isabelle; Azim, Hatem A; Peccatori, Fedro A.

In: Breast, Vol. 42, 22.08.2018, p. 41-49.

Research output: Contribution to journalArticle

Lambertini, Matteo ; Di Maio, Massimo ; Pagani, Olivia ; Curigliano, Giuseppe ; Poggio, Francesca ; Del Mastro, Lucia ; Paluch-Shimon, Shani ; Loibl, Sibylle ; Partridge, Ann H ; Demeestere, Isabelle ; Azim, Hatem A ; Peccatori, Fedro A. / The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. In: Breast. 2018 ; Vol. 42. pp. 41-49.
@article{ffb3f62c4b5141b2862a07c935959b64,
title = "The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients",
abstract = "BACKGROUND: Fertility and pregnancy-related issues are major concerns for young breast cancer patients. Limited data are available on physicians' knowledge, attitudes and practice in these fields.METHODS: A 26-item questionnaire exploring 3 different topics (fertility preservation, pregnancy after breast cancer and breast cancer during pregnancy) was sent by email to physicians attending the 2016 3rd European School of Oncology (ESO) - European Society for Medical Oncology (ESMO) Breast Cancer in Young Women Conference (BCY3) and the 15th St. Gallen International Breast Cancer Conference 2017 (BCC 2017). Given the selected sample, survey respondents were expected to have a higher than average interest in the management of breast cancer patients. Descriptive analyses were performed.RESULTS: A total of 273 physicians (105 at BCY3 and 168 at BCC 2017) completed the survey; 37.0{\%}, 46.9{\%} and 34.8{\%} reported never having consulted the available international guidelines on fertility preservation, pregnancy after breast cancer and management of breast cancer during pregnancy, respectively. Up to 18.3{\%} of respondents did not know if the different fertility preservation options were available in their country; 22.3{\%} suggested that controlled ovarian stimulation should not be considered safe in patients with hormone receptor-positive disease. A total of 30.4{\%} of respondents agreed or were neutral on the statement that pregnancy in breast cancer survivors may increase the risk of recurrence. Regarding breast cancer during pregnancy, 23.8{\%} and 38.1{\%} disagreed or were neutral on the statements that endocrine therapy and anti-HER2 agents should be avoided during pregnancy, respectively.CONCLUSIONS: Further educational initiatives are needed to improve physicians' knowledge and adherence to available guidelines when addressing fertility and pregnancy-related issues in young breast cancer patients.",
author = "Matteo Lambertini and {Di Maio}, Massimo and Olivia Pagani and Giuseppe Curigliano and Francesca Poggio and {Del Mastro}, Lucia and Shani Paluch-Shimon and Sibylle Loibl and Partridge, {Ann H} and Isabelle Demeestere and Azim, {Hatem A} and Peccatori, {Fedro A}",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
month = "8",
day = "22",
doi = "10.1016/j.breast.2018.08.099",
language = "English",
volume = "42",
pages = "41--49",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients

AU - Lambertini, Matteo

AU - Di Maio, Massimo

AU - Pagani, Olivia

AU - Curigliano, Giuseppe

AU - Poggio, Francesca

AU - Del Mastro, Lucia

AU - Paluch-Shimon, Shani

AU - Loibl, Sibylle

AU - Partridge, Ann H

AU - Demeestere, Isabelle

AU - Azim, Hatem A

AU - Peccatori, Fedro A

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018/8/22

Y1 - 2018/8/22

N2 - BACKGROUND: Fertility and pregnancy-related issues are major concerns for young breast cancer patients. Limited data are available on physicians' knowledge, attitudes and practice in these fields.METHODS: A 26-item questionnaire exploring 3 different topics (fertility preservation, pregnancy after breast cancer and breast cancer during pregnancy) was sent by email to physicians attending the 2016 3rd European School of Oncology (ESO) - European Society for Medical Oncology (ESMO) Breast Cancer in Young Women Conference (BCY3) and the 15th St. Gallen International Breast Cancer Conference 2017 (BCC 2017). Given the selected sample, survey respondents were expected to have a higher than average interest in the management of breast cancer patients. Descriptive analyses were performed.RESULTS: A total of 273 physicians (105 at BCY3 and 168 at BCC 2017) completed the survey; 37.0%, 46.9% and 34.8% reported never having consulted the available international guidelines on fertility preservation, pregnancy after breast cancer and management of breast cancer during pregnancy, respectively. Up to 18.3% of respondents did not know if the different fertility preservation options were available in their country; 22.3% suggested that controlled ovarian stimulation should not be considered safe in patients with hormone receptor-positive disease. A total of 30.4% of respondents agreed or were neutral on the statement that pregnancy in breast cancer survivors may increase the risk of recurrence. Regarding breast cancer during pregnancy, 23.8% and 38.1% disagreed or were neutral on the statements that endocrine therapy and anti-HER2 agents should be avoided during pregnancy, respectively.CONCLUSIONS: Further educational initiatives are needed to improve physicians' knowledge and adherence to available guidelines when addressing fertility and pregnancy-related issues in young breast cancer patients.

AB - BACKGROUND: Fertility and pregnancy-related issues are major concerns for young breast cancer patients. Limited data are available on physicians' knowledge, attitudes and practice in these fields.METHODS: A 26-item questionnaire exploring 3 different topics (fertility preservation, pregnancy after breast cancer and breast cancer during pregnancy) was sent by email to physicians attending the 2016 3rd European School of Oncology (ESO) - European Society for Medical Oncology (ESMO) Breast Cancer in Young Women Conference (BCY3) and the 15th St. Gallen International Breast Cancer Conference 2017 (BCC 2017). Given the selected sample, survey respondents were expected to have a higher than average interest in the management of breast cancer patients. Descriptive analyses were performed.RESULTS: A total of 273 physicians (105 at BCY3 and 168 at BCC 2017) completed the survey; 37.0%, 46.9% and 34.8% reported never having consulted the available international guidelines on fertility preservation, pregnancy after breast cancer and management of breast cancer during pregnancy, respectively. Up to 18.3% of respondents did not know if the different fertility preservation options were available in their country; 22.3% suggested that controlled ovarian stimulation should not be considered safe in patients with hormone receptor-positive disease. A total of 30.4% of respondents agreed or were neutral on the statement that pregnancy in breast cancer survivors may increase the risk of recurrence. Regarding breast cancer during pregnancy, 23.8% and 38.1% disagreed or were neutral on the statements that endocrine therapy and anti-HER2 agents should be avoided during pregnancy, respectively.CONCLUSIONS: Further educational initiatives are needed to improve physicians' knowledge and adherence to available guidelines when addressing fertility and pregnancy-related issues in young breast cancer patients.

U2 - 10.1016/j.breast.2018.08.099

DO - 10.1016/j.breast.2018.08.099

M3 - Article

VL - 42

SP - 41

EP - 49

JO - Breast

JF - Breast

SN - 0960-9776

ER -